Home
Healthcare Global Enterprises Share Price Target 2025, 2026, 2027 to 2030

Healthcare Global Enterprises Share Price Target 2025, 2026, 2027 to 2030

Price Target March 11, 2025 0
Tweet
Share
Pin
Share
0 Shares

Healthcare Global Enterprises Ltd. (HCG), headquartered in Bangalore, India, is a leading healthcare organization established in 1998. Renowned as the largest cancer care provider in the country, HCG operates 24 specialized cancer centers, delivering integrated oncology care through surgical, radiation, and medical treatments under one roof. The organization also manages a nationally recognized tertiary care hospital, offering advanced technology, exceptional medical expertise, and comprehensive healthcare services. Additionally, HCG operates fertility centers under the Milann brand, providing cutting-edge reproductive medicine, including assisted reproduction, gynecological endoscopy, and fertility preservation. HCG’s commitment to care, cure, and comfort is evident in its state-of-the-art facilities and patient-centric approach. Listed on NSE and BSE, the company is a prominent player in hospital management and medical diagnostics, contributing significantly to India’s healthcare landscape while earning multiple accolades for its innovative and quality-driven services.

Shareholdings Patterns of Healthcare Global Enterprises

Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024
Promoters +71.29%71.28%71.26%71.23%71.22%
FIIs +6.37%6.74%3.95%4.30%2.77%
DIIs +8.46%8.52%10.89%11.64%12.94%
Public +13.89%13.45%13.90%12.84%13.07%
No. of Shareholders27,28927,19526,52929,67032,820

The shareholding pattern of Healthcare Global Enterprises Ltd. shows notable trends across different stakeholder categories over the specified period. As of December 2023, promoters held a dominant stake of 71.29%, slightly decreasing to 71.22% by December 2024. Foreign Institutional Investors (FIIs) showed fluctuations, starting at 6.37% in December 2023, peaking at 6.74% in March 2024, and subsequently declining to 2.77% by December 2024. Domestic Institutional Investors (DIIs) increased their stake significantly, from 8.46% in December 2023 to 12.94% by December 2024, reflecting growing domestic confidence in the company. Public shareholding remained relatively stable, with minor fluctuations, ranging from 13.89% in December 2023 to 13.07% by the end of 2024. Additionally, the number of shareholders witnessed an upward trend, growing from 27,289 in December 2023 to 32,820 in December 2024, indicating increased investor interest in Healthcare Global Enterprises Ltd.

News on Healthcare Global Enterprises

KKR has acquired a majority stake in Healthcare Global Enterprises (HCG), buying 51%-54% of its equity from CVC Asia V at ₹445 per share. This transaction, valued at a significant premium, triggers an open offer under SEBI’s Takeover Regulations, allowing other shareholders to tender their shares. The acquisition highlights KKR’s focus on India’s healthcare sector and its confidence in HCG’s leadership in oncology care, with plans to support its growth and innovation in cancer treatment across the country.

How to Purchase Healthcare Global Enterprises Shares in India?

Below are the trading platforms that you can use to purchase Healthcare Global Enterprises shares:

➤ Zerodha

➤ Upstox

➤ Groww

➤ AngelOne

➤ ICICIDirect

Healthcare Global Enterprises Share Price Target 2025 – 2030

Healthcare Global Enterprises Share Price Prediction 2025

WhenMaximum PriceMinimum Price
April 2025571.77439.82
May 2025555.12427.01
June 2025580.10446.23
July 2025568.72437.48
August 2025586.31451.01
September 2025593.35456.42
October 2025608.77468.29
November 2025623.99479.99
December 2025652.07501.59

As we step into April 2025, the share price of Healthcare Global Enterprises is expected to reach a maximum of ₹571.77 and a minimum of ₹439.82. By June, prices may rise to ₹580.10 and ₹446.23, respectively, while July could see a slight dip with ₹568.72 as the maximum and ₹437.48 as the minimum. Moving into September, the prices are anticipated to peak at ₹593.35 and ₹456.42. As we step into December 2025, the share price is projected to achieve its highest yearly value at ₹652.07 and a minimum of ₹501.59, reflecting consistent growth.

Finances rule

Healthcare Global Enterprises Share Price Target 2026

WhenMaximum PriceMinimum Price
January 2026671.63516.64
February 2026654.84503.73
March 2026667.94513.80
April 2026681.57524.29
May 2026674.82519.10
June 2026691.69532.07
July 2026678.13521.64
August 2026699.10537.77
September 2026713.09548.53
October 2026731.63562.79
November 2026749.92576.86
December 2026768.67591.28

As we move into January 2026, the share price of Healthcare Global Enterprises is expected to reach a maximum of ₹671.63 and a minimum of ₹516.64. February may witness a slight decline, with prices projected at ₹654.84 and ₹503.73, respectively. By April, the values are anticipated to climb to ₹681.57 and ₹524.29. June could see further growth, reaching ₹691.69 at its peak and ₹532.07 at its lowest. As we move into September, prices are likely to peak at ₹713.09 and dip to ₹548.53. Finally, as we move into December 2026, the share price is forecasted to attain a maximum of ₹768.67 and a minimum of ₹591.28.

Healthcare Global Enterprises Share Price Prediction 2027

WhenMaximum PriceMinimum Price
January 2027776.35597.19
February 2027796.26612.51
March 2027827.31636.39
April 2027811.09623.92
May 2027787.47605.74
June 2027822.90633.00
July 2027806.77620.59
August 2027831.72639.78
September 2027860.83662.18
October 2027883.21679.39
November 2027905.29696.38
December 2027927.92713.79

Healthcare Global Enterprises Share Price Target 2028

WhenMaximum PriceMinimum Price
January 2028946.48728.06
February 2028970.75746.73
March 20281,008.61775.85
April 2028988.83760.64
May 2028960.03738.49
June 20281,003.23771.72
July 2028983.56756.59
August 20281,013.98779.99
September 20281,049.47807.29
October 20281,076.76828.28
November 20281,103.68848.98
December 20281,131.27870.21

Healthcare Global Enterprises Share Price Prediction 2029

WhenMaximum PriceMinimum Price
January 20291,153.89887.61
February 20291,183.48910.37
March 20291,229.64945.87
April 20291,205.53927.33
May 20291,170.41900.32
June 20291,223.08940.83
July 20291,199.10922.39
August 20291,236.19950.91
September 20291,279.45984.19
October 20291,312.721,009.78
November 20291,345.541,035.03
December 20291,379.181,060.90

Healthcare Global Enterprises Share Price Target 2030

WhenMaximum PriceMinimum Price
January 20301,406.761,082.12
February 20301,442.831,109.87
March 20301,499.101,153.15
April 20301,469.711,130.54
May 20301,426.901,097.61
June 20301,491.111,147.01
July 20301,461.871,124.52
August 20301,507.081,159.30
September 20301,559.831,199.87
October 20301,600.391,231.07
November 20301,640.401,261.84
December 20301,681.411,293.39

As we move through 2030, Healthcare Global Enterprises‘ share prices are expected to showcase significant growth. In January 2030, the shares are projected to reach a maximum price of ₹1,406.76 and a minimum price of ₹1,082.12. By December 2030, Healthcare Global Enterprises‘ shares are anticipated to rise further, with a maximum price of ₹1,681.41 and a minimum price of ₹1,293.39.

Financial Condition of Healthcare Global Enterprises

Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024TTM
Sales +1,0921,0091,3951,6911,9082,132
Expenses +9368871,1611,3941,5811,759
Operating Profit157122234297327374
OPM %14%12%17%18%17%18%
Other Income +10-72110152434
Interest13811998104109137
Depreciation148159158163174199
Profit before tax-119-22988456872
Tax %5%-3%56%61%39%
Net Profit +-125-22139184166
EPS in Rs-12.03-15.433.872.113.464.19
Dividend Payout %0%0%0%0%0%

The financial performance of Healthcare Global Enterprises showcases a notable improvement over the years, reflecting its strategic growth and operational resilience. Sales have steadily increased from ₹1,092 crore in March 2020 to ₹2,132 crore in the trailing twelve months (TTM), indicating consistent revenue growth. Operating profit has also improved, rising from ₹157 crore in March 2020 to ₹374 crore in the TTM, with the operating profit margin (OPM%) stabilizing at 18%, signifying efficiency in cost management.

Although the company faced net losses of ₹125 crore in March 2020 and ₹221 crore in March 2021, Healthcare Global Enterprises transitioned to profitability with a net profit of ₹66 crore in the TTM. This turnaround is supported by disciplined expense management and an increase in other income. The earnings per share (EPS) have improved significantly, from a loss of ₹12.03 in March 2020 to ₹4.19 in the TTM, reflecting enhanced shareholder value. Despite the financial progress, the company has maintained a dividend payout of 0%, likely reinvesting earnings to support its expansion and growth strategies.

FAQs

What is the current market capitalization of Healthcare Global Enterprises?

Healthcare Global Enterprises current market capitalization stands at ₹7,031 crore.

What is the current share price of Healthcare Global Enterprises?

As of March 11th, 2025, Healthcare Global Enterprises share price is ₹504.

What are the expected share price targets for Healthcare Global Enterprises in 2025?

Healthcare Global Enterprises expected share price targets for 2025 range from ₹427.01 to ₹652.07.

What are the forecasted share price targets for Healthcare Global Enterprises in 2030?

Healthcare Global Enterprises forecasted share price targets for 2030 range from ₹1,082.12 to ₹1,681.41.

Also Read

Conclusion

Healthcare Global Enterprises Ltd. (HCG) has solidified its position as a leading cancer care provider and a significant player in India’s healthcare landscape. The company has demonstrated consistent growth in its financial performance, with rising sales and improved operating margins, though it has faced challenges with net profits in earlier years. Its shareholding patterns indicate stable promoter confidence and increasing domestic institutional investor interest, while public and FII holdings show minor fluctuations.

HCG’s share price projections for 2025-2030 suggest a strong upward trajectory, supported by its innovative approach, state-of-the-art facilities, and expanding investor base. Strategic developments, such as KKR’s acquisition, further underscore its potential for growth and innovation in oncology care and beyond, making HCG a prominent entity in India’s healthcare sector.

Financesrule telegram

Author: Ashnoor

Related

Leave a Reply